바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.72 No.4
Citation Share

Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2012, v.72 no.4, pp.381-385
https://doi.org/10.4046/trd.2012.72.4.381
Su Jin Yoo (Chungnam National University)

(Chungnam National University Hospital)
Sun Young Jung (Chungnam National University Hospital)
Dong Il Park (Chungnam National University Hospital)
Myoung Rin Park (Chungnam National University Hospital)
Hee Sun Park (Chungnam National University Hospital)


Su, J. Y. , Sun, Y. J. , Dong, I. P. , Myoung, R. P. , Hee, S. P. , & (2012). Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment. Tuberculosis & Respiratory Diseases, 72(4), 381-385, https://doi.org/10.4046/trd.2012.72.4.381
  • Downloaded
  • Viewed
PDF Download

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths. Most patients were presented with advanced disease at the time of diagnosis. In advanced NSCLC, it is almost impossible to anticipate complete remission by using only cytotoxic chemotherapy or molecularly targeted agents. In our case, two patients were diagnosed as advanced NSCLC and received chemotherapy. They achieved complete response (CR). After finishing treatment, disease recurred. They were retreated with the same regimens and achieved second CR. Until now,they have received each regimen, continuously, and the CR state has been maintained.

keywords
Carcinoma, Non-Small-Cell Lung, Remission Induction, Retreatment, Maintenance Chemotherapy

Reference

1.

1. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.

2.

2. Lee SY, Park JY. Personalized therapy in lung cancer: focused on molecular targeted therapy. J Lung Cancer 2011;10:1-12.

3.

3. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.

4.

4. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7: 51.

5.

5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer, v.3. Fort Washington, PA: National Comprehensive Cancer Network; 2011.

6.

6. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001;12:23-7.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy